The granting of this waiver now enables the Company to develop Brilacidin in a more focused manner in adult patient populations where Oral Mucositis has the greatest impact.

They could have used this opportunity to further explain its meaning.

NOT just for HNC patients. Seem like a simple thing? This opens the door for even more potential $$$.

Let's get that license Dr. B!!!